Date:3/4/2013

e 3: Paroxysmal Nocturnal Hemoglobinuria, UK, Revenue Forecast ($m), 2011-2019 13
Figure 4: Paroxysmal Nocturnal Hemoglobinuria, France, Revenue Forecast ($m), 2011-2019 14
Figure 5: Paroxysmal Nocturnal Hemoglobinuria, Germany, Revenue Forecast ($m), 2011-2019 14
Figure 6: Paroxysmal Nocturnal Hemoglobinuria, Italy, Revenue Forecast ($m), 2011-2019 15
Figure 7: Paroxysmal Nocturnal Hemoglobinuria, Spain, Revenue Forecast ($m), 2011-2019 15
Figure 8: Paroxysmal Nocturnal Hemoglobinuria, Japan, Revenue Forecast ($m), 2011-2019 16
Figure 9: Paroxysmal Nocturnal Hemoglobinuria, Total Market, Average Annual Cost of Therapy (%), 2011-2019 17
Figure 10: Paroxysmal Nocturnal Hemoglobinuria, Treatment Usage Pattern ('000), 2011-2019 18
Figure 11: Paroxysmal Nocturnal Hemoglobinuria, Pipeline Overview 21
Figure 12: Paroxysmal Nocturnal Hemoglobinuria, Pipeline by Therapeutic Class 23
Figure 13: Paroxysmal Nocturnal Hemoglobinuria, Pipeline by Molecule Type 23
Figure 14: Paroxysmal Nocturnal Hemoglobinuria, Pipeline by Mechanism of Action 24
Figure 15: Idiopathic Thrombocytopenic Purpura, Underlying Mechanism 25
Figure 16: Idiopathic Thrombocytopenic Purpura, Total Market, Revenue Forecast ($m), 2011-2019 27
Figure 17: Idiopathic Thrombocytopenic Purpura, US, Revenue Forecast ($m), 2011-2019 28
Figure 18: Idiopathic Thrombocytopenic Purpura, UK, Revenue Forecast ($m), 2011-2019 28
Figure 19: Idiopathic Thrombocytopenic Purpura, France, Revenue Forecast ($m), 2011-2019 29
Figure 20: Idiopathic Thrombocytopenic Purpura, Germany, Revenue Forecast ($m), 2011-2019 29
Figure 21: Idiopathic Thrombocytopenic Purpura, Italy, Revenue Forecast ($m), 2011-2019 30
Figure 22: Idiopathic Thrombocytopenic Purpura
'/>"/>

SOURCE Reportlinker Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10
Related medicine technology :

1. Founder of Nestle-Acquired Company Joins Prismic Pharmaceuticals
2. Young Innovations Announces Definitive Agreement to be Acquired by Linden Capital Partners
3. Bandages Plus, Inc. Doral, Florida has been acquired by The Morrissey Group, LLC
4. Pathogenica and Life Technologies EMEA Partner to Control Hospital Acquired Infections
5. Medisafe 1 Technologies Corp has of Today Acquired 3,100,000 Shares and Continues to Acquire Shares Under its $1MM Stock Repurchase Program of 10MM Shares up to 10 Cents a Share to Facilitate its On-going Acquisitions Activity Plan
6. Inspiration Biopharmaceuticals Reports Positive Interim Results from the Accur8 Phase 2/3 Study of OBI-1 in Acquired Hemophilia A at WFH 2012 World Congress
7. Kensey Nash Agrees to Be Acquired by DSM for $38.50 per Share in Cash
8. FDA Grants Orphan Drug Status To Eisais Lenvatinib
9. Lentigen Receives U.S. Orphan Drug Designation for Novel Gene Therapy for glioblastoma multiforme
10. BHR Pharma Investigational Traumatic Brain Injury Treatment Receives European Medicines Agency Orphan Medicinal Product Designation
11. Inherited Orphan Blood Disorders Therapeutics Market to 2019 - Breakthrough Drugs Remain Elusive Against Backdrop of High Unmet Need